Navigation Links
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
Date:10/29/2008

CLA). "Data from these trials also showed that a greater percentage of patients achieved a 15 percent improvement in FEV1 within 15 minutes with SYMBICORT as compared to budesonide and placebo on the day of randomization and end of treatment."(5)

SHINE Study Results (Abstracts 298 and SHINE Safety)

The efficacy and tolerability of SYMBICORT was assessed in a six-month, randomized, double-blind, multicenter trial evaluating 1,704 patients ages 40 years and older with moderate to very severe COPD.(1,2) After two weeks of treatment based on previous therapy (inhaled corticosteroids (ICS) and short-acting bronchodilators were allowed), patients were then randomized to receive twice-daily treatment with two inhalations of SYMBICORT pMDI 160/4.5 micrograms (mcg), SYMBICORT pMDI 80/4.5 mcg, budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg, budesonide pMDI 160 mcg, formoterol DPI 4.5 mcg or placebo.(1,2) Study results include:

-- Both SYMBICORT doses (160/4.5 and 80/4.5 mcg) demonstrated a significantly greater improvement from baseline in pre-dose forced expiratory volume in one second (FEV1) (P Less Than or Equal To .001) and one-hour post-dose FEV1 compared with budesonide (P<.001).(1)

-- SYMBICORT 160/4.5 mcg also demonstrated a significant (P=.026) improvement from baseline for pre-dose FEV1 compared with formoterol.(1)

-- Improvements from baseline in morning and evening peak expiratory flow (PEF) were significantly (P Less Than or Equal To .016) greater for both SYMBICORT doses compared with formoterol, budesonide and placebo.(1)

-- Both SYMBICORT doses significantly (P<.028) improved the sum of Breathlessness, Cough and Sputum Scores (BCSS), sleep score, awakening-free nights, and rescue medication use versus placebo.(1)

-- Both doses of SYMBICORT were well-tolerated for six months relative to its monocomponents and placebo.(2) The incidence of pneumonia-related adverse events were similar for all treatment arms compa
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Recruitment Completed in Ofatumumab NHL Pivotal Study
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
9. 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
10. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
11. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, announced today ... Hercules Technology Growth Capital, Inc. (NYSE: HTGC ... advance under the Loan and Security Agreement that Alimera,s ... Alimera Sciences Limited, entered into with Hercules in April ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... CAMBRIDGE, Mass., Dec. 22, 2011  Inspiration Biopharmaceuticals, Inc. ... the development and commercialization of new treatment options ... Company has expanded its leadership team with four ... Inspiration as Chief Medical Officer; Daniel Regan as ...
... Dec. 22, 2011  PTC Therapeutics, Inc. (PTC) today ... Drug Discovery (SDD) Award from the Wellcome Trust ... target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative ... Award from the Wellcome Trust to support its ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 2Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 3Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 4Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 5PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... say finding could be key to new disease-fighting therapies ... on mice suggests inhibiting a protein that allows certain ... to cancer-fighting treatments. , A study by Pierre Sonveaux ... found that tumor cells use different fuel sources depending ...
... A team of researchers at Duke University Medical Center and ... acid is an important energy source for tumor cells. In ... most hard-to-kill, dangerous tumor cells by preventing them from delivering ... than 50 years that low-oxygen, or hypoxic, cells cause resistance ...
... MORRISTOWN, N.J., Nov. 20 /PRNewswire/ Bayer HealthCare,has donated hundreds ... New Jersey,(CFBNJ) in response to an urgent call from ... supplies at the state,s food banks. , ... , Mary Lou Panzano, director, US Internal ...
... cancer patients who underwent a mastectomy who undergo ... reconstruction provides fewer long-term complications and better cosmetic ... to a study in the November issue of ... the official journal of the American Society for ...
... Alzheimer,s relatives at risk for hospital visits of their own ... providing care for a loved one with Alzheimer,s results in ... room or hospital visit every six months, says an Indiana ... care of an Alzheimer,s patient is difficult, but the Indiana ...
... Centre Finalizes Construction Plan and Begins Marketing; John Strong, ... Inc., to Lead Sales and Marketing Efforts , ... The world,s first permanent international healthcare marketplace and ... the key players driving the project said today, as ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2Health News:Type of breast reconstruction impacts radiation therapy outcomes 2Health News:When the Caregiver Becomes the Patient 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... PulmoAide Compact Compressor provides effective therapy at an ... therapy at home or on the go and ... the same reliable operation you have come to ... Compressor is the perfect solution for those patients ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Medicine Products: